Skip to main content
Clinical Trials/CTRI/2018/01/011118
CTRI/2018/01/011118
Completed
Phase 3

A single-blinded, randomized clinical study to evaluate and compare the safety and efficacy of a test hair leave-on product (Hair Tonic) with a comparator product for scalp hair growth and density in healthy male and female subjects

ITC Life Sciences Technology Centre0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
ITC Life Sciences Technology Centre
Enrollment
100
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 21, 2017
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
ITC Life Sciences Technology Centre

Eligibility Criteria

Inclusion Criteria

  • 1Subjects to be 21 to 55 year old and generally in good health
  • 2Female subjects falling under grade 2, 3 and grade 4 of hair loss severity index as per Ludwig Photo numeric scale.
  • 3Male subjects falling under grade 2, 3 and grade 4 of hair loss severity index as per modified Norwood scale.
  • 4Subject having hair density of 100\-200 /cm2\.
  • 5Subjects with \> 15 strands of fallen hair as assessed by comb test
  • 6Subjects willing to participate in the study voluntarily and agreeing to give their consent for their participation in the study in a signed document.
  • 7Subjects agreeing to maintain the same hairstyle, hair length and hair color throughout the study
  • 8Subjects consenting to have a dot tattoo or markings placed in the target area of the scalp during the study
  • 9Subjects Willing to maintain the habits and products during the study
  • 10Subjects consenting to comply with the study requirements for 6 consecutive months

Exclusion Criteria

  • 1Subjects who have undergone hair growth treatment 3 months before screening into the study under discussion.
  • 2Subjects having scalp conditions such as folliculitis, seborrheoic psoriasis of scalp, seborrheoic dermatitis and lichen planopilaris at the time of screening.
  • 3Subjects with alopecia areata of scalp hair and scarring alopecia due to any cause such as DLE, SLE and Lichen planus.
  • 4Subjects who have undergone hair straightening using hot iron or chemicals within 3 months prior to the screening.
  • 5Subjects who have undergone treatments of cancer chemotherapy within 6 months before starting study or plan to undergo the same during study course.
  • 6Subjects with a history of alcoholism and/ or psychiatric disorder including trichotillomania.
  • 7Subjects who have had hair transplantation treatment.
  • 8Subjects who take pharmaceutical products that may cause hirsutism (ex. phenytoin) and finesteride for androgenic alopecia.
  • 9Subjects with a known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
  • 10Subjects on oral medications (e.g. steroids, anti\-oxidant) which will compromise the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials